Eli Lilly Posts Strong Q2 Earnings but GLP-1 Pill Disappointment Weighs on Stock
Zepbound and Mounjaro Drive U.S. Sales, Yet Orforglipron Trial Results Raise Investor Concerns Eli Lilly (LLY) delivered a solid second-quarter ...
Tag: LLY
Novo Nordisk’s CagriSema Trial Results Shake Market Confidence
Disappointing Data Spurs $125 Billion Market Value Drop Novo Nordisk’s (NVO) ambitions in the competitive obesity drug market took a ...
